Ehp Funds Inc. Abb Vie Inc. Transaction History

Ehp Funds Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $325,059 - $379,596	2,100 New	2,100 $360,000
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $1.03 Million - $1.19 Million	-7,700 Reduced 81.91%	1,700 $253,000
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $1.44 Million - $1.8 Million	-10,900 Reduced 53.69%	9,400 $1.27 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $375,986 - $433,004	-2,600 Reduced 11.35%	20,300 $3.24 Million
Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $207,465 - $248,805	-1,500 Reduced 6.15%	22,900 $3.7 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $1.69 Million - $1.94 Million	12,600 Added 106.78%	24,400 $3.28 Million
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $784,434 - $997,272	5,700 Added 93.44%	11,800 $1.81 Million
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $805,077 - $998,875	6,100 New	6,100 $989,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Ehp Funds Inc., based on Form 13F filings with the SEC.

Stay updated on Ehp Funds Inc. with notifications on news.